Old drugs, new tricks: leveraging known compounds to disrupt coronavirus-induced cytokine storm.

Richman, Spencer; Lyman, Cole; Nesterova, Anastasia; Yuryev, Anton; Morris, Matthew; Cao, Hongbao; Cheadle, Chris; Skuse, Gary; Broderick, Gordon

Richman, Spencer; Lyman, Cole; Nesterova, Anastasia; Yuryev, Anton; Morris, Matthew; Cao, Hongbao; Cheadle, Chris; Skuse, Gary; Broderick, Gordon.

Afiliação

Richman S; Rochester General Hospital, Center for Clinical Systems Biology, Rochester, NY, USA.
Lyman C; Rochester General Hospital, Center for Clinical Systems Biology, Rochester, NY, USA.
Nesterova A; Elsevier BV, Biology Solutions, Amsterdam, the Netherlands.
Yuryev A; Elsevier BV, Biology Solutions, Amsterdam, the Netherlands.
Morris M; Rochester General Hospital, Center for Clinical Systems Biology, Rochester, NY, USA.
Cao H; Elsevier BV, Biology Solutions, Amsterdam, the Netherlands.
Cheadle C; Elsevier BV, Biology Solutions, Amsterdam, the Netherlands.
Skuse G; Rochester Institute of Technology, Gosnell School of Life Sciences, Rochester, NY, USA.
Broderick G; Rochester General Hospital, Center for Clinical Systems Biology, Rochester, NY, USA. gordon.broderick@rochesterregional.org.

NPJ Syst Biol Appl ; 8(1): 38, 2022 10 10.

Article em En | MEDLINE | ID: mdl-36216820

Assuntos

Tratamento Farmacológico da COVID-19; Inibidores de Hidroximetilglutaril-CoA Redutases; Calcineurina; Síndrome da Liberação de Citocina/tratamento farmacológico; Dexametasona; Humanos; SARS-CoV-2

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 1_ASSA2030 Base de dados: MEDLINE Assunto principal: Inibidores de Hidroximetilglutaril-CoA Redutases / Tratamento Farmacológico da COVID-19 Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: NPJ Syst Biol Appl Ano de publicação: 2022 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google